The Macular Minute Episode 5
with Sobha Sivaprasad
Holistic Costs Associated with anti-VEGF Treatment
In this 4-minute episode, we are joined by Sobha Sivaprasad, a Consultant Ophthalmologist at Moorfields Eye Hospital NHS Foundation Trust, to discuss the holistic costs associated with anti-VEGF treatment.
This promotional podcast series has been organised and funded by Bayer and is for UK healthcare professionals only.
Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.
Prescribing information for EYLEA® (aflibercept) 2 mg can be found here.
Sobha Sivaprasad
Professor Sobha Sivaprasad is a medical retina consultant ophthalmologist at Moorfields Eye Hospital with expertise in Diabetic Retinopathy, Retinal Vein Occlusions, Macular Degeneration and other retinal conditions. She is the director of the National Institute for Health and Care Research (NIHR) Moorfields Clinical Research Facility and the chair of the Scientific Committee of the Royal College of Ophthalmologists, and has published over 500 peer-reviewed articles.
Speaker Disclosures
Financial support from AbbVie, Amgen, Apellis Pharmaceuticals, Bayer, Biogen, Boehringer Ingelheim, Eyebiotech, EyePoint Pharmaceuticals, Janssen Pharmaceuticals, Kriya Therapeutics, Novartis, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Roche, Sanofi and Stealth BioTherapeutics
References
- Sivaprasad, S. et al. (2024) ‘Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis’, Current Medical Research and Opinion, 40(7), pp. 1221–1233. doi: 10.1080/03007995.2024.2362278. Available at: https://www.tandfonline.com/doi/full/10.1080/03007995.2024.2362278. Accessed: December 2024. This paper has been initiated and funded by Bayer.
- EYLEA® 40 mg/mL Summary of Product Characteristics.
- EYLEA® 114.3 mg/mL Summary of Product Characteristics.
PP-EYL-GB-2545 | December 2024